ReviewJournal of thrombosis and haemostasis : JTH2019
Engineered microparticles and nanoparticles for fibrinolysis.
Review in Journal of thrombosis and haemostasis : JTH, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 35 citations in OpenAlex.
- Multivalent Bi-Specific Nanoerythrosomes: A Two-Birds-One-Stone Approach to Combine Homologous and Active Targeting for Effective Thrombolysis.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Optimized TELIP, an Echogenic Liposomal Nano-Carrier Loaded with Alteplase for Preclinical Studies.Pharmaceutics · 2026Article
- Micro/Nanorobotic Systems for Imaging-Guided Closed-Loop Thrombus Recanalization.Cyborg and bionic systems (Washington, D.C.) · 2026Review
- Emerging Thrombolysis Technologies in Vascular Thrombosis.Journal of clinical medicine · 2025Review
- Micrometer-scale tPA beads amplify plasmin generation for enhanced thrombolytic therapy.Bioengineering & translational medicine · 2025Article
- Photothrombolytics: A light-driven technology for the targeted lysis of thrombi.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Magnetically powered microwheel thrombolysis of occlusive thrombi in zebrafish.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Research into New Molecular Mechanisms in Thrombotic Diseases Paves the Way for Innovative Therapeutic Approaches.International journal of molecular sciences · 2024Review
- Magnetically Powered Microwheel Thrombolysis of Occlusive Thrombi in Zebrafish.bioRxiv : the preprint server for biology · 2023Article
- Direct delivery of plasmin using clot-anchoring thrombin-responsive nanoparticles for targeted fibrinolytic therapy.Journal of thrombosis and haemostasis : JTH · 2023Article
- Magnetic Nanoparticles Mediated Thrombolysis-A Review.IEEE open journal of nanotechnology · 2023Article
- A Fibrinogen-Mimicking, Activated-Platelet-Sensitive Nanocoacervate Enhances Thrombus Targeting and Penetration of Tissue Plasminogen Activator for Effective Thrombolytic Therapy.Advanced healthcare materials · 2022Article
- Pathophysiology of Coagulation and Emerging Roles for Extracellular Vesicles in Coagulation Cascades and Disorders.Journal of clinical medicine · 2022Review
- Platelet-inspired nanomedicine in hemostasis thrombosis and thromboinflammation.Journal of thrombosis and haemostasis : JTH · 2022Review
- Breaking the fibrinolytic speed limit with microwheel co-delivery of tissue plasminogen activator and plasminogen.Journal of thrombosis and haemostasis : JTH · 2022Article
- Nanomaterials as Ultrasound Theragnostic Tools for Heart Disease Treatment/Diagnosis.International journal of molecular sciences · 2022Review
- Theranostic nanoparticles for the management of thrombosis.Theranostics · 2022Review
- Multiphysics Modelling and Simulation of Thrombolysis via Activated Platelet-Targeted Nanomedicine.Pharmaceutical research · 2022Article
- Thrombolytic Agents: Nanocarriers in Targeted Release.Molecules (Basel, Switzerland) · 2021Review
- Heparin and Arginine Based Plasmin Nanoformulation for Ischemic Stroke Therapy.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Fibrinolytic agents including plasmin and plasminogen activators improve outcomes in acute ischemic stroke and thrombosis by recanalizing occluded vessels. In the decades since their introduction into clinical practice, several limitations of have been identified in terms of both efficacy and bleeding risk associated with these agents. Engineered nanoparticles and microparticles address some of these limitations by improving circulation time, reducing inhibition and degradation in circulation, accelerating recanalization, improving targeting to thrombotic occlusions, and reducing off-target effects; however, many particle-based approaches have only been used in preclinical studies to date. This review covers four advances in coupling fibrinolytic agents with engineered particles: (a) modifications of plasminogen activators with macromolecules, (b) encapsulation of plasminogen activators and plasmin in polymer and liposomal particles, (c) triggered release of encapsulated fibrinolytic agents and mechanical disruption of clots with ultrasound, and (d) enhancing targeting with magnetic particles and magnetic fields. Technical challenges for the translation of these approaches to the clinic are discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.